Gilead Sciences takes a hit after a Wall Street Journal reports state that the Trump administration is looking to slash ...

We suggest that investors who own GSK's stock remain invested for now, considering its sales and profits are expected to continue improving in the coming years.

The Health and Human Services Department is considering cuts to HIV prevention funding, according to The Wall Street Journal.

GSK’s ViiV Healthcare has shared clinical data on three potential long-acting HIV treatments, providing a look at how its ...

A group of more than 100 Democratic lawmakers sent a letter to President Donald Trump on Friday warning about the potential ...

ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early ...

Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...

The Department of Health and Human Services (HHS) is reportedly poised to slash funding for domestic HIV prevention at the ...

The HIV Drugs Market is expected to grow steadily from 2025 to 2035, driven by advancements in antiretroviral therapy and increasing global awareness initiatives. Rising HIV prevalence, improved ...

Gilead Sciences (GILD) stock fell after The Wall Street Journal reported that the Health and Human Services Department is looking at ...

George House Trust, which helps people across Greater Manchester and Liverpool, was one of 10 winners of the 2025 GSK Impact ...